Is platelet activating factor (PAF) a mediator of endotoxin shock?

European Journal of Pharmacology
Z TerashitaS Sumida

Abstract

To determine whether endogenous PAF contributes to the pathogenesis of endotoxin shock, CV-3988, a specific PAF antagonist, was injected i.v. to rats before, simultaneously with or after endotoxin. CV-3988 (5 mg/kg i.v.) injected 5 min before the endotoxin completely inhibited endotoxin (15 mg/kg i.v.)-induced hypotension, and CV-3988 (0.05-1 mg/kg i.v.) injected 7-10 min after the endotoxin rapidly reversed endotoxin-induced hypotension. A combination of CV-3988 (10 mg/kg) with endotoxin (5 mg/kg) administered i.v. improved the survival rate for 20 h or more. CV-3988 (0.05-1 mg/kg i.v.) rapidly reversed the PAF (1 microgram/kg i.v.)-induced hypotension. These findings strongly suggest that endogenous PAF may play a pivotal role in the pathogenesis of endotoxin shock.

References

Aug 1, 1983·Agents and Actions·N Semeraro, A Lattanzio
Apr 25, 1983·Life Sciences·Z TerashitaK Nishikawa
Jan 21, 1983·European Journal of Pharmacology·P BessinJ Benveniste

Citations

Feb 1, 1988·Digestive Diseases and Sciences·J L Wallace, B J Whittle
Jan 1, 1986·Immunologic Research·B Beutler, A Cerami
May 28, 1992·Biochemical Pharmacology·B KlosterhalfenP C Heinrich
Jun 10, 1988·European Journal of Pharmacology·J LefortB B Vargaftig
May 10, 1988·European Journal of Pharmacology·G L StahlA M Lefer
Jan 3, 1991·European Journal of Pharmacology·F SquadritoA P Caputi
Jun 5, 1992·European Journal of Pharmacology·J M HerbertJ P Maffrand
Aug 22, 1994·European Journal of Pharmacology·G EmanuelliG Camussi
Jul 1, 1986·Prostaglandins·J L Wallace, B J Whittle
Jan 1, 1988·Molecular Aspects of Medicine·N C OlsonC E McCall
Aug 1, 1989·Molecular Immunology·M A SmalJ W Redmond
Jan 1, 1991·General Pharmacology·A MiyamotoH Ohshika
Mar 1, 1990·Research in Immunology·Y DenizotJ Benveniste
Jan 1, 1993·International Journal of Antimicrobial Agents·S Q DeJoyS S Kerwar
Nov 14, 1996·European Journal of Pharmacology·G E JarvisM F Heath
Apr 23, 1997·European Journal of Pharmacology·D H AlbertG W Carter
May 22, 1998·General Pharmacology·B Klosterhalfen, R S Bhardwaj
Jan 1, 1997·Journal of Lipid Mediators and Cell Signalling·J M HerbertE Tibiriça
Feb 15, 1988·European Journal of Biochemistry·Y SuzukiM Matsumoto
Nov 15, 1991·European Journal of Biochemistry·G CamussiF Bussolino
Dec 1, 1992·The Australian and New Zealand Journal of Surgery·J Ludbrook
Nov 1, 1990·Journal of Veterinary Internal Medicine·E M Hardie, K Kruse-Elliott
Nov 1, 1996·The Journal of Pharmacy and Pharmacology·A A Izzo
Nov 1, 1990·Gut·Y DenizotJ Benveniste
May 1, 1987·The Journal of Clinical Investigation·S W ChangN F Voelkel
May 1, 1989·The Journal of Clinical Investigation·F Lopez DiezM Sanchez Crespo
Mar 1, 1990·World Journal of Surgery·T Hau
May 1, 1991·Journal of Veterinary Internal Medicine·D D Morris
May 25, 1993·Biochemical Pharmacology·T IchoK Kubota
Feb 1, 1987·Pharmacological Research Communications·A BrambillaA Giachetti
Sep 1, 1991·Prostaglandins, Leukotrienes, and Essential Fatty Acids·R D EvansD H Williamson
Dec 1, 1990·Clinical Immunology and Immunopathology·G CamussiC Baglioni
Sep 1, 1989·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·V LagenteP Braquet
Oct 21, 2003·The Journal of Physiology·Andrei I IvanovAndrej A Romanovsky
Jan 1, 1988·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·T KobayashiS Tanayama
Feb 1, 1997·Japanese Circulation Journal·T TamuraM Inada
Mar 1, 1997·The Journal of Surgical Research·K EphgraveJ Cullen
Jan 1, 1987·British Journal of Pharmacology·M Criscuoli, A Subissi
Jan 15, 1992·Thrombosis Research·K SawadaT Abe
Aug 1, 1988·Scandinavian Journal of Gastroenterology·A BerstadB I Hirschowitz
Oct 26, 1999·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·S B MustafaM S Olson
May 1, 1992·Circulation Research·S YamanakaK Yamamoto
Jan 31, 2014·The Journal of Biological Chemistry·Johanna RiveraDavid L Goldman
Apr 1, 1989·Medicinal Research Reviews·K H Weber, H O Heuer
Nov 1, 1989·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·F GuarnerJ Rodés
Jan 1, 1990·Scandinavian Journal of Gastroenterology. Supplement·S J Konturek
Feb 12, 1987·The New England Journal of Medicine·B Beutler, A Cerami
Feb 23, 2000·Journal of Cardiovascular Pharmacology and Therapeutics·U Pattanaik, K Prasad
Jan 1, 1991·Research in Experimental Medicine. Zeitschrift Für Die Gesamte Experimentelle Medizin Einschliesslich Experimenteller Chirurgie·S B FelixW E Berdel
Oct 4, 2000·Physiological Reviews·G MontrucchioG Camussi
Feb 1, 1988·The American Journal of Physiology·C H LangJ J Spitzer

Related Concepts

CV 3988
Metazoa
Diastolic Blood Pressure
Endotoxins
1-Alkyl-2-Acylphosphatidates
Platelet Activating Factor
August Rats
Endotoxic Shock
Thiazoles
Rats, Laboratory

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Lipidomics & Rhinovirus Infection

Lipidomics can be used to examine the lipid species involved with pathogenic conditions, such as viral associated inflammation. Discovered the latest research on Lipidomics & Rhinovirus Infection.

Alzheimer's Disease: MS4A

Variants within the membrane-spanning 4-domains subfamily A (MS4A) gene cluster have recently been implicated in Alzheimer's disease in genome-wide association studies. Here is the latest research on Alzheimer's disease and MS4A.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Torsion Dystonia

Torsion dystonia is a movement disorder characterized by loss of control of voluntary movements appearing as sustained muscle contractions and/or abnormal postures. Here is the latest research.

Generating Insulin-Secreting Cells

Reprogramming cells or using induced pluripotent stem cells to generate insulin-secreting cells has significant therapeutic implications for diabetics. Here is the latest research on generation of insulin-secreting cells.

Central Pontine Myelinolysis

Central Pontine Myelinolysis is a neurologic disorder caused most frequently by rapid correction of hyponatremia and is characterized by demyelination that affects the central portion of the base of the pons. Here is the latest research on this disease.

Epigenome Editing

Epigenome editing is the directed modification of epigenetic marks on chromatin at specified loci. This tool has many applications in research as well as in the clinic. Find the latest research on epigenome editing here.